Long-term safety in adults with X-linked Hypophosphatemia (XLH) treated with Burosumab, a fully human monoclonal antibody against FGF23: Final results of a phase 3 trial

• Peter Kamenický,
• Anthony A. Portale,
• Tom Carpenter,
• Karine Briot,
• Erik A. Imel,
• Thomas Weber,
• Pisit Pitukcheewanont,
• Hae Il Cheong,
• Suzanne Jan de Beur,
• Yasuo Imanishi,
• Nobuaki Ito,
• Robin Lachmann,
• Hiroyuki Tanaka,
• Farzana Perwad,
• Lin Zhang,
• Alison Skrinar,
• Linda Rees,
• Karl L. Insogna

Affiliations

Peter Kamenický

Université Paris-Sud, Le Kremlin Bicêtre, Paris, France; Corresponding author.

Anthony A. Portale

University of California San Francisco, San Francisco, United States

Tom Carpenter

Yale School of Medicine, New Haven, United States

Karine Briot

Centre d'Evaluation des Maladies Osseuses, Hôpital Cochin, Paris, France

Erik A. Imel

Indiana University School of Medicine, Indianapolis, United States

Thomas Weber

Duke University Medical Center, Durham, United States

Pisit Pitukcheewanont

Children's Hospital Los Angeles, University of Southern California Keck School of Medicine, Los Angeles, United States

Hae Il Cheong

Seoul National University Children's Hospital, Seoul, Republic of Korea

Suzanne Jan de Beur

Johns Hopkins University, Baltimore, United States

Yasuo Imanishi

Osaka City University Graduate School of Medicine, Osaka, Japan

Nobuaki Ito

The University of Tokyo Hospital, Tokyo, Japan

Robin Lachmann

University College London Hospitals, London, United Kingdom

Hiroyuki Tanaka

Okayama Saiseikai General Hospital, Okayama, Japan

Farzana Perwad

University of California San Francisco, San Francisco, United States

Lin Zhang

Ultragenyx Pharmaceutical Inc, Novato, United States

Alison Skrinar

Ultragenyx Pharmaceutical Inc, Novato, United States

Linda Rees

Ultragenyx Pharmaceutical Inc, Novato, United States

Karl L. Insogna

Yale School of Medicine, New Haven, United States